+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Diabetes Drug Market, Size, Forecast 2022-2027, Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis

  • PDF Icon

    Report

  • 140 Pages
  • March 2022
  • Region: Global
  • Renub Research
  • ID: 5562695
Global Diabetes Drug Market is estimated to reach US$ 82.92 Billion in 2027. Diabetes is a long-term condition indicated by high blood sugar levels. It is caused by a malfunction in the pancreas, which secretes insulin. Besides, diabetes is also referred to as diabetes mellitus. High blood sugar levels cause thirst, hunger, and frequent urination. Diabetes complications such as diabetes ketoacidosis, heart disease, stroke, and kidney failure are caused by a lack of treatment. Diabetes is treated with insulin infusion therapy - diabetes medications aid in preventing complications and controlling blood glucose levels. Metformin, Actos, Avandia, Lantus subcutaneous, and invokana are medications used to treat type 2 diabetes. All medicines are taken orally except for insulin, exenatide, liraglutide, and pramlintide.



Worldwide Diabetes Drug Market Size was US$ 63.13 Billion in 2021


Diabetes drugs have been used more frequently in recent years as the prevalence of diabetes has increased across all age groups. Some of the critical elements driving growth in the diabetes drugs market include an aging population, technological advancements, and increased sales of novel drugs.

Besides, government initiatives to combat diabetes are fueling the growth of the diabetes drugs market. The high manufacturing costs of drugs and insulin devices, on the other hand, are limiting the development of the diabetes drugs market. Furthermore, a lack of public awareness about diabetes treatment impedes the growth of the diabetes drugs market. As per the publisher, Global Diabetes Drug Industry will expand with a CAGR of 4.6% during 2021-2027.

Synopsis of COVID-19 Impact on the Global Diabetes Drug Market:


The appearance of COVID-19 had brought the world to a halt. The healthcare crisis had a far-reaching impact on businesses across industries. The pandemic underscored the importance of chronic disease management and its role in public health. People with diabetes were at the highest risk of becoming infected with the virus. As a result, population healthcare systems have prioritized infrastructure consolidation to improve chronic disease care. As a result, the current drug market is boosted, encouraging R&D investments. Furthermore, increased public awareness aided patients in making more clinically informed decisions about the pharmacological therapies required.

Disease Type: Type 2 Diabetes Holds Prominent Position:


Our report classifies the diabetes drug market into type 1 diabetes and type 2 diabetes. Remarkably, due to higher prevalence worldwide, type 2 diabetes contributes significantly to the diabetes drugs market. Furthermore, rising obesity rates, rising disposable income, and improved healthcare facilities are some of the key factors driving the growth of the diabetes type 2 segment. Meanwhile, type 1 diabetes is expected to follow the type 2 segment and rise rapidly during the forecast period.

By Therapy, the Market for Insulin Remains Dominant:


In this report, we have furnished a comprehensive analysis of the global diabetes drug market and divided it into three segments: Oral, Injectable, and Insulin. According to our research, the demand for insulin remains dominant, owing to imperfect competition from biosimilars in the market and patients' lack of trust in biosimilars.

In addition, we have examined the sub-segments for the segments as mentioned earlier based on therapy. Precisely, (DPP) IV inhibitor, SGLT-2, Alpha Glucosidase Inhibitor, and Biguanide are Oral Drug sub-segments, Glucagon-like peptide (GLP) 1 agonist, and Amylin receptor agonist are Injection Drug sub-segments and Rapid - Acting Insulin, Long-Acting Insulin, and Premixed Insulin are Insulin sub-segments covered in our report.

The America Accounts for Lion's Share:


America holds the lion's share in 2021 and is expected to maintain its dominance throughout the forecast period. This is primarily due to an increase in the diabetes population in the American region due to stress, unhealthy diets, and obesity. Besides, there are over million diabetes patients in the American region, and this number is expected to ascend in the forthcoming years, according to our analysis.

Furthermore, the growth of the diabetes drug market in this region is aided by favorable government reimbursement policies and advanced healthcare infrastructure. Aside from that, Asia-Pacific countries are expected to generate higher demand in the coming years, owing primarily to initiatives undertaken by local governments and health organizations to raise awareness about diabetes, drugs, and devices.

Competitive Landscape:


The diabetes drugs market is relatively fragmented, with only major and generic players. The few significant players studied in our report include Novo Nordisk, AstraZeneca plc, Biocon, Sanofi, Eli Lilly, Johnson & Johnson, and Bristol Myers Squibb Co. The competition among the participants is high, as each is attempting to develop new drugs and offer them at competitive prices. Furthermore, players are expanding into new markets to increase their market share, particularly in emerging economies where demand exceeds supply.

The publisher's latest report Diabetes Drug Market, Global Forecast By Disease Type (Type 1 Diabetes Drug Market and Type 2 Diabetes Drug Market), Therapy (Oral ((DPP) IV inhibitor, SGLT-2, Alpha Glucosidase Inhibitor, and Biguanide), Injection (Glucagon-like peptide (GLP) 1 agonist, and Amylin receptor agonist), Insulin (Rapid - Acting Insulin, Long-Acting Insulin, and Premixed Insulin ), Region ( America, Europe, Asia Pacific, The Middle East & Africa), Companies (Novo Nordisk, AstraZeneca plc, Biocon, Sanofi, Eli Lilly, Johnson & Johnson, and Bristol Myers Squibb Co) provides a detailed analysis of Diabetes Drug Industry.

Disease Type - Market has been covered from 2 viewpoints:


1. Type 1 Diabetes Drug Market
2. Type 2 Diabetes Drug Market

Therapy - Market have been covered from 3 viewpoints:


1. Oral
  • (DPP) IV inhibitor
  • SGLT - 2
  • Alpha Glucosidase Inhibitor
  • Biguanide
  • Others Oral Drug

2. Injection
  • Glucagon-like peptide (GLP) 1 agonist
  • Amylin receptor agonist

3. Insulin
  • Rapid - Acting Insulin
  • Long Acting Insulin
  • Premixed Insulin
  • Other Insulin

Region - Market have been covered from 4 viewpoints:


1. North America
2. Europe
3. Asia Pacific
4. Middle East & Africa

Company Insights:


  • Overview
  • Recent Development & Strategies
  • Financial Insights

Companies Covered:


1. Novo Nordisk
2. AstraZeneca plc
3. Biocon
4. Sanofi
5. Eli Lilly
6. Johnson & Johnson
7. Bristol Myers Squibb Co.
Frequently Asked Questions about the Global Diabetes Drugs Market

What is the estimated value of the Global Diabetes Drugs Market?

The Global Diabetes Drugs Market was estimated to be valued at $63.13 Billion in 2021.

What is the growth rate of the Global Diabetes Drugs Market?

The growth rate of the Global Diabetes Drugs Market is 4.6%, with an estimated value of $82.92 Billion by 2027.

What is the forecasted size of the Global Diabetes Drugs Market?

The Global Diabetes Drugs Market is estimated to be worth $82.92 Billion by 2027.

Who are the key companies in the Global Diabetes Drugs Market?

Key companies in the Global Diabetes Drugs Market include Novo Nordisk, AstraZeneca plc, Biocon, Sanofi, Eli Lilly and Bristol Myers Squibb Co..

Table of Contents

1. Introduction2. Research & Methodology3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Diabetes Drugs Market
6. Market Share - Global Diabetes Drugs Market
6.1 By Disease Type
6.2 By Therapy - (Oral, Injection, Insulin)
6.3 By Oral Drug
6.4 By Injection Drug
6.5 By Insulin
6.6 By Regions
7. Disease Type - Global Diabetes Drugs Market
7.1 Type 1 Diabetes Drug Market
7.2 Type 2 Diabetes Drug Market
8. Therapy - Global Diabetes Drugs Market
8.1 Oral
8.1.1 (DPP) IV inhibitor
8.1.2 SGLT - 2
8.1.3 Alpha Glucosidase Inhibitor
8.1.4 Biguanide
8.1.5 Others Oral Drug
8.2 Injection
8.2.1 Glucagon-like peptide (GLP) 1 agonist
8.2.2 Amylin receptor agonist
8.3 Insulin
8.3.1 Rapid - Acting Insulin
8.3.2 Long Acting Insulin
8.3.3 Premixed Insulin
8.3.4 Other Insulin
9. Region - Global Diabetes Drugs Market
9.1 North America
9.2 Europe
9.3 Asia Pacific
9.4 The Middle East & Africa
10. Porters Five Forces
10.1 Overview
10.2 Bargaining Power of Buyers
10.3 Bargaining Power of Suppliers
10.4 Degree of Competition
10.5 Threat of New Entrants
10.6 Threat of Substitutes
11. Company Analysis
11.1 Novo Nordisk
11.1.1 Overview
11.1.2 Recent Development & Strategies
11.1.3 Financial Insights
11.2 AstraZeneca plc
11.2.1 Overview
11.2.2 Recent Development & Strategies
11.2.3 Financial Insights
11.3 Biocon
11.3.1 Overview
11.3.2 Recent Development & Strategies
11.3.3 Financial Insights
11.4 Sanofi
11.4.1 Overview
11.4.2 Recent Development & Strategies
11.4.3 Financial Insights
11.5 Eli Lilly
11.5.1 Overview
11.5.2 Recent Development & Strategies
11.5.3 Financial Insights
11.6 Johnson & Johnson
11.6.1 Overview
11.6.2 Recent Development & Strategies
11.6.3 Financial Insights
11.7 Bristol Myers Squibb Co.
11.7.1 Overview
11.7.2 Recent Development & Strategies
11.7.3 Financial Insights
List Of Figures:
Figure 01: Global - Diabetes Drug Market (Million US$), 2016 - 2021
Figure 02: Global - Forecast for Diabetes Drug Market (Million US$), 2022 - 2027
Figure 03: Disease Type - Type 1 Diabetes Drug Market Market (Million US$), 2016 - 2021
Figure 04: Disease Type - Forecast for Type 1 Diabetes Drug Market Market (Million US$), 2022 - 2027
Figure 05: Disease Type - Type 2 Diabetes Drug Market Market (Million US$), 2016 - 2021
Figure 06: Disease Type - Forecast for Type 2 Diabetes Drug Market Market (Million US$), 2022 - 2027
Figure 07: Oral - (DPP) IV inhibitor Market (Million US$), 2016 - 2021
Figure 08: Oral - Forecast for (DPP) IV inhibitor Market (Million US$), 2022 - 2027
Figure 09: Oral - SGLT - 2 Market (Million US$), 2016 - 2021
Figure 10: Oral - Forecast for SGLT - 2 Market (Million US$), 2022 - 2027
Figure 11: Oral - Alpha Glucosidase Inhibitor Market (Million US$), 2016 - 2021
Figure 12: Oral - Forecast for Alpha Glucosidase Inhibitor Market (Million US$), 2022 - 2027
Figure 13: Oral - Biguanide Market (Million US$), 2016 - 2021
Figure 14: Oral - Forecast for Biguanide Market (Million US$), 2022 - 2027
Figure 15: Oral - Others Oral Drug Market (Million US$), 2016 - 2021
Figure 16: Oral - Forecast for Others Oral Drug Market (Million US$), 2022 - 2027
Figure 17: Injection - Glucagon-like peptide (GLP) 1 agonist Market (Million US$), 2016 - 2021
Figure 18: Injection - Forecast for Glucagon-like peptide (GLP) 1 agonist Market (Million US$), 2022 - 2027
Figure 19: Injection - Amylin receptor agonist Market (Million US$), 2016 - 2021
Figure 20: Injection - Forecast for Amylin receptor agonist Market (Million US$), 2022 - 2027
Figure 21: Insulin - Rapid - Acting Insulin Market (Million US$), 2016 - 2021
Figure 22: Insulin - Forecast for Rapid - Acting Insulin Market (Million US$), 2022 - 2027
Figure 23: Insulin - Long Acting Insulin Market (Million US$), 2016 - 2021
Figure 24: Insulin - Forecast for Long Acting Insulin Market (Million US$), 2022 - 2027
Figure 25: Insulin - Premixed Insulin Market (Million US$), 2016 - 2021
Figure 26: Insulin - Forecast for Premixed Insulin Market (Million US$), 2022 - 2027
Figure 27: Insulin - Other Insulin Market (Million US$), 2016 - 2021
Figure 28: Insulin - Forecast for Other Insulin Market (Million US$), 2022 - 2027
Figure 29: America - Diabetes Drug Market (Million US$), 2016 - 2021
Figure 30: America - Forecast for Diabetes Drug Market (Million US$), 2022 - 2027
Figure 31: Europe - Diabetes Drug Market (Million US$), 2016 - 2021
Figure 32: Europe - Forecast for Diabetes Drug Market (Million US$), 2022 - 2027
Figure 33: Asia Pacific - Diabetes Drug Market (Million US$), 2016 - 2021
Figure 34: Asia Pacific - Forecast for Diabetes Drug Market (Million US$), 2022 - 2027
Figure 35: Middle East & Africa - Diabetes Drug Market (Million US$), 2016 - 2021
Figure 36: Middle East & Africa - Forecast for Diabetes Drug Market (Million US$), 2022 - 2027
Figure 37: Novo Nordisk - Global Revenue (Million US$), 2016 - 2021
Figure 38: Novo Nordisk - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 39: AstraZeneca plc - Global Revenue (Million US$), 2016 - 2021
Figure 40: AstraZeneca plc - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 41: Biocon - Global Revenue (Million US$), 2016 - 2021
Figure 42: Biocon - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 43: Sanofi - Global Revenue (Million US$), 2016 - 2021
Figure 44: Sanofi - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 45: Eli Lilly - Global Revenue (Million US$), 2016 - 2021
Figure 46: Eli Lilly - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 47: Johnson & Johnson - Global Revenue (Million US$), 2016 - 2021
Figure 48: Johnson & Johnson - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 49: Bristol Myers Squibb Co. - Global Revenue (Million US$), 2016 - 2021
Figure 50: Bristol Myers Squibb Co. - Forecast for Global Revenue (Million US$), 2022 - 2027
List Of Tables:
Table 01: Global - Diabetes Drug Market Share by Disease Type (Percent), 2016 - 2021
Table 02: Global - Forecast for Diabetes Drug Market Share by Disease Type (Percent), 2022 - 2027
Table 03: Global - Diabetes Drug Market Share by Therapy (Percent), 2016 - 2021
Table 04: Global - Forecast for Diabetes Drug Market Share by Therapy (Percent), 2022 - 2027
Table 05: Global - Diabetes Drug Market Share by Oral Drug (Percent), 2016 - 2021
Table 06: Global - Forecast for Diabetes Drug Market Share by Oral Drug (Percent), 2022 - 2027
Table 07: Global - Diabetes Drug Market Share by Injection Drug (Percent), 2016 - 2021
Table 08: Global - Forecast for Diabetes Drug Market Share by Injection Drug (Percent), 2022 - 2027
Table 09: Global - Diabetes Drug Market Share by Insulin (Percent), 2016 - 2021
Table 10: Global - Forecast for Diabetes Drug Market Share by Insulin (Percent), 2022 - 2027
Table 11: Global - Diabetes Drug Market Share by Region (Percent), 2016 - 2021
Table 12: Global - Forecast for Diabetes Drug Market Share by Region (Percent), 2022 - 2027

Companies Mentioned

  • Novo Nordisk
  • AstraZeneca plc
  • Biocon
  • Sanofi
  • Eli Lilly
  • Johnson & Johnson
  • Bristol Myers Squibb Co.

Methodology

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...